Drug Profile
HR 1671A
Latest Information Update: 09 Jul 2002
Price :
$50
*
At a glance
- Originator Aventis
- Class Antihyperlipidaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Atherosclerosis
Most Recent Events
- 24 Dec 1999 Hoechst Marion Roussel has merged with Rhône-Poulenc Rorer to form Aventis Pharma
- 19 Jun 1997 Phase-I clinical trials for Atherosclerosis in European Union (Unknown route)